Australasian Business Intelligence - Weight-loss medication under scrutiny.
Saturday, November 15th, 2008By Rebecca Jenkins
LANCET A review of anti-obesity drugs suggests their use is limited by modest efficacy and the low numbers of patients who persist with treatment.
The analysis, which included orlistat (Xenical), sibutramine (Reductil) and rimonabant (Acomplia), concluded that studies of anti-obesity drugs to date were notable for their high attrition rates and lack of data on major …
